Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$170.26+2.68 (+1.60%)
Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%
Gilead Sciences gross margin
Gross margin is gross profit as a percentage of revenue.
Gilead Sciences's gross margin for the twelve months ending Sep 30, 2026 was 79.9%. For fiscal 2025 it was 78.8%, against 78.3% the year before. The highest annual figure on record is 87.7% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 78.8% | +0.6 |
| FY2024 | Dec 31, 2024 | 78.3% | +2.2 |
| FY2023 | Dec 31, 2023 | 76.0% | −3.2 |
| FY2022 | Dec 31, 2022 | 79.3% | +3.4 |
| FY2021 | Dec 31, 2021 | 75.8% | −5.7 |
| FY2020 | Dec 31, 2020 | 81.5% | +2.3 |
| FY2019 | Dec 31, 2019 | 79.2% | +1.1 |
| FY2018 | Dec 31, 2018 | 78.1% | −5.2 |
| FY2017 | Dec 31, 2017 | 83.3% | −2.7 |
| FY2016 | Dec 31, 2016 | 86.0% | −1.7 |
| FY2015 | Dec 31, 2015 | 87.7% | +2.9 |
| FY2014 | Dec 31, 2014 | 84.8% | +10.3 |
| FY2013 | Dec 31, 2013 | 74.5% | −0.1 |
| FY2012 | Dec 31, 2012 | 74.5% | −0.1 |
| FY2011 | Dec 31, 2011 | 74.7% | −1.8 |
| FY2010 | Dec 31, 2010 | 76.5% | −0.8 |
| FY2009 | Dec 31, 2009 | 77.2% | −1.6 |
| FY2008 | Dec 31, 2008 | 78.9% | −3.0 |
| FY2007 | Dec 31, 2007 | 81.8% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 81.1% | +1.3 |
| Q2 FY2026 | Jun 30, 2026 | 79.8% | +1.0 |
| Q1 FY2026 | Mar 31, 2026 | 79.2% | +2.3 |
| Q4 FY2025 | Dec 31, 2025 | 79.5% | +0.4 |
| Q3 FY2025 | Sep 30, 2025 | 79.8% | +0.7 |
| Q2 FY2025 | Jun 30, 2025 | 78.8% | +1.0 |
| Q1 FY2025 | Mar 31, 2025 | 76.9% | +0.1 |
| Q4 FY2024 | Dec 31, 2024 | 79.1% | +8.5 |
| Q3 FY2024 | Sep 30, 2024 | 79.1% | +1.3 |
| Q2 FY2024 | Jun 30, 2024 | 77.8% | −0.4 |
| Q1 FY2024 | Mar 31, 2024 | 76.8% | −1.2 |
| Q4 FY2023 | Dec 31, 2023 | 70.6% | −10.5 |
| Q3 FY2023 | Sep 30, 2023 | 77.8% | −2.4 |
| Q2 FY2023 | Jun 30, 2023 | 78.1% | +1.2 |
| Q1 FY2023 | Mar 31, 2023 | 77.9% | −0.4 |
| Q4 FY2022 | Dec 31, 2022 | 81.1% | +17.4 |
| Q3 FY2022 | Sep 30, 2022 | 80.2% | −3.3 |
| Q2 FY2022 | Jun 30, 2022 | 77.0% | −0.7 |
| Q1 FY2022 | Mar 31, 2022 | 78.4% | −0.4 |
| Q4 FY2021 | Dec 31, 2021 | 63.7% | −16.2 |
| Q3 FY2021 | Sep 30, 2021 | 83.5% | +2.1 |
| Q2 FY2021 | Jun 30, 2021 | 77.6% | −0.2 |
| Q1 FY2021 | Mar 31, 2021 | 78.8% | −2.3 |
| Q4 FY2020 | Dec 31, 2020 | 79.9% | +9.9 |
| Q3 FY2020 | Sep 30, 2020 | 81.4% | +1.4 |
| Q2 FY2020 | Jun 30, 2020 | 77.8% | −3.2 |
| Q1 FY2020 | Mar 31, 2020 | 81.1% | +0.7 |
| Q4 FY2019 | Dec 31, 2019 | 70.0% | −1.0 |
| Q3 FY2019 | Sep 30, 2019 | 80.0% | +1.9 |
| Q2 FY2019 | Jun 30, 2019 | 81.0% | +4.1 |
| Q1 FY2019 | Mar 31, 2019 | 80.3% | +1.7 |
| Q4 FY2018 | Dec 31, 2018 | 70.9% | −6.1 |
| Q3 FY2018 | Sep 30, 2018 | 78.1% | −4.4 |
| Q2 FY2018 | Jun 30, 2018 | 76.9% | −6.0 |
| Q1 FY2018 | Mar 31, 2018 | 78.6% | −4.7 |
| Q4 FY2017 | Dec 31, 2017 | 77.0% | −6.9 |
| Q3 FY2017 | Sep 30, 2017 | 82.5% | – |
| Q2 FY2017 | Jun 30, 2017 | 82.9% | – |
| Q1 FY2017 | Mar 31, 2017 | 83.3% | – |
| Q4 FY2016 | Dec 31, 2016 | 83.9% | – |
See a number that looks wrong?